Johns Creek, Georgia, U.S., October 7, 2026
Boehringer Ingelheim has announced the availability of a new Quarterable Snap-Tab design for PREVICOX® (firocoxib) Chewable Tablets in the United States following approval by the U.S. Food and Drug Administration (FDA). The redesigned tablets are intended to provide veterinarians with more flexible and precise dosing options for dogs based on body weight, while improving convenience for pet owners. The update introduces a double-scoring design that allows tablets to be divided into quarters, creating additional dosage options for the veterinary medicine used to control pain and inflammation in dogs. The company also says the updated tablet and packaging design offers sustainability benefits by helping reduce product waste and packaging material use.
New PREVICOX Design Enables More Flexible Dosing
The new Quarterable Snap-Tab design features double scoring to make it easier to divide PREVICOX tablets into four portions. This design allows veterinarians to tailor doses more precisely to a dog’s weight and individual treatment requirements. According to Boehringer Ingelheim, the updated design supports dosing options for dogs weighing as little as seven pounds, expanding flexibility for veterinary professionals treating smaller dogs. The redesign introduces additional dosage options using the existing 57 mg and 227 mg chewable tablet strengths. PREVICOX contains firocoxib, a cyclooxygenase-2 (COX-2)-selective non-steroidal anti-inflammatory drug (NSAID). It is approved for controlling pain and inflammation associated with osteoarthritis in dogs and for managing postoperative pain and inflammation following soft-tissue and orthopedic surgery. Dr. Russ Drury, Executive Director of Veterinary Professional Services at Boehringer Ingelheim, said the updated tablet design offers benefits for veterinarians and dog owners by making individualized dosing easier. The company expects the added flexibility to support treatment decisions and help improve convenience for dogs requiring pain and inflammation management. Veterinarians should determine the appropriate dose for each animal according to the product’s prescribing information and the dog’s clinical needs.
Updated Packaging Supports Sustainability Goals
Alongside the tablet redesign, Boehringer Ingelheim is introducing packaging changes intended to improve efficiency and reduce waste. Quartered PREVICOX tablets may be stored in their container for up to one month after division, according to the company’s announcement. This feature can help owners manage divided doses while reducing the likelihood of unnecessary product waste. The bottle design will also change to an industry-standard round bottle with a taller profile. In addition, the company plans to remove the cotton currently included in the packaging. These modifications are intended to reduce packaging material use and simplify supply-chain requirements across the product lifecycle. Despite these changes, several product characteristics will remain unchanged. The formulation, full-tablet strengths of 57 mg and 227 mg, bottle counts, push-and-turn opening and closing system, and child-resistant and senior-friendly packaging characteristics will be retained. The company plans to introduce the new design progressively throughout 2026 and 2027, beginning with the 227 mg and 57 mg presentations in 60-count bottles.
Advertisement
Veterinary Safety and Product Availability
PREVICOX remains a prescription veterinary medicine intended for use in dogs only. Like other NSAIDs that inhibit cyclooxygenase, firocoxib may be associated with gastrointestinal, kidney, or liver side effects. Boehringer Ingelheim advises that dogs should be evaluated for pre-existing conditions and current medications before treatment begins and monitored regularly during therapy. Concurrent use with another NSAID, a corticosteroid, or a nephrotoxic medication should be avoided or closely monitored, as appropriate under veterinary guidance. The new quarterable design changes the tablet’s physical configuration and packaging, but the company states that the underlying formulation remains the same. The updated PREVICOX presentation reflects Boehringer Ingelheim’s continued efforts to improve the usability of established veterinary medicines. By combining more flexible tablet division with packaging changes, the company aims to offer practical dosing options for veterinarians and dog owners while supporting more efficient product use. The gradual rollout will bring the redesigned tablets to U.S. customers during 2026 and 2027.
Source: Boehringer Ingelheim press release
